<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716842</url>
  </required_header>
  <id_info>
    <org_study_id>AOzer2</org_study_id>
    <nct_id>NCT04716842</nct_id>
  </id_info>
  <brief_title>Evaluation of Plasma Angiotensin II and Angiotensin II Receptor Levels in Patients With Sepsis and Septic Shock: a Prospective Observational Study.</brief_title>
  <official_title>Evaluation of Plasma Angiotensin II and Angiotensin II Receptor Levels in Patients With Sepsis and Septic Shock: a Prospective Observational Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of plasma angiotensin II and angiotensin II receptor levels in patients with&#xD;
      sepsis and septic shock: a prospective observational study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an increasing number of experimental publications investigated effects of&#xD;
      angiotensin II and receptors on the pathogenesis and treatment of sepsis and septic shock.&#xD;
      However, its level in humans and its relationship with the severity of the disease has not&#xD;
      been investigated. If angiotensin II plays a role in the diagnosis and prognosis of septic&#xD;
      shock by evaluating this relationship in our study, it may be a biomarker to be used in&#xD;
      future diagnosis, prediction of prognosis and treatment. This will enable early recognition&#xD;
      and treatment of this disease, which causes high mortality and cost in intensive care units,&#xD;
      thus increasing the survival rate and reducing the cost.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>angiotensin II levels</measure>
    <time_frame>0-3 days</time_frame>
    <description>serum angiotensin II levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>angiotensin II receptor I</measure>
    <time_frame>0-3 days</time_frame>
    <description>serum angiotensin II receptor I levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>angiotensin II receptor II</measure>
    <time_frame>0-3 days</time_frame>
    <description>serum angiotensin II receptor II levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>procalsitonine level</measure>
    <time_frame>0-3 days</time_frame>
    <description>Procalsitonine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>crp level</measure>
    <time_frame>0-3 days</time_frame>
    <description>crp levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>sepsis</arm_group_label>
    <description>In intensive care patients with suspected or proven infection, if the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination, monitoring and treatment will be applied.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>septic shock</arm_group_label>
    <description>Patients with sepsis who require vasopressor to keep mean arterial pressure above 65 mmHg and lactate&gt; 2 mmol/l will be included in the septic shock group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>It will be formed from patients who are hospitalized in the intensive care unit for a reason other than sepsis and septic shock, without suspected or proven infection.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Group sepsis (n = 25): In intensive care patients with suspected or proven infection, if&#xD;
        the SOFA score ≥2, the patients will be evaluated as sepsis and routine examination,&#xD;
        monitoring and treatment will be applied.&#xD;
&#xD;
        Group septic shock (n = 25): Patients with sepsis who require vasopressor to keep mean&#xD;
        arterial pressure above 65 mmHg and lactate&gt; 2 mmol/l will be included in the septic shock&#xD;
        group.&#xD;
&#xD;
        Group Control (n = 25): It will be formed from patients who are hospitalized in the&#xD;
        intensive care unit for a reason other than sepsis and septic shock, without suspected or&#xD;
        proven infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  intensive care unit patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  End-stage organ failure,&#xD;
&#xD;
          -  immunodeficiency, vasospastic disease, pregnancy, other shock causes (hypovolemic,&#xD;
             cardiogenic, neurogenic) a life expectancy of less than 48 hours&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Ayse Belin B OZER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inonu University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayse Belin B OZER</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 16, 2021</study_first_submitted>
  <study_first_submitted_qc>January 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>January 16, 2021</last_update_submitted>
  <last_update_submitted_qc>January 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Ayse Belin Ozer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>angiotensin II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

